Breaking News Instant updates and real-time market news.

MRK

Merck

$62.86

0.195 (0.31%)

16:06
10/07/16
10/07
16:06
10/07/16
16:06

Merck Animal Health receives USDA approval of canine flu bivalent vaccine

Merck Animal Health announced that the U.S. Department of Agriculture has approved a license for Nobivac Canine Flu Bivalent vaccine - the first vaccine to aid in the control of disease associated with both canine influenza virus H3N2 and canine influenza virus H3N8. CIV H3N2 was identified last year in the United States following multiple outbreaks throughout the country. "Merck Animal Health has a rich history of vaccine development supported by a wealth of expertise, as well as a deep commitment to bringing innovative products to market that truly impact the health and well-being of animals," said KJ Varma, BVSc, Ph.D., senior vice president, R&D, Merck Animal Health. "Our new bivalent canine influenza vaccine will simplify protection against this disease and is a tremendous example of our ongoing pursuit of the science of healthier animals and our dedication to providing veterinarians with new medicines and vaccines to advance optimal pet care."

  • 07

    Oct

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.86

0.195 (0.31%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

TXMD

TherapeuticsMD

$6.15

-0.09 (-1.44%)

06:49
01/16/18
01/16
06:49
01/16/18
06:49
Recommendations
TherapeuticsMD analyst commentary  »

TherapeuticsMD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

MRK

Merck

$58.66

1.06 (1.84%)

06:46
01/16/18
01/16
06:46
01/16/18
06:46
Hot Stocks
Merck: Phase 3 KEYNOTE-189 trial met dual primary endpoints »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 25

    Mar

  • 03

    Apr

  • 23

    Oct

SPX

S&P 500

06:45
01/16/18
01/16
06:45
01/16/18
06:45
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

, DDAIF

Daimler AG

$90.25

1.44 (1.62%)

06:41
01/16/18
01/16
06:41
01/16/18
06:41
Periodicals
Fiat Chrysler, Daimler warn over Europe's emissions targets, FT says »

Fiat Chrysler (FCAU) and…

FCAU

Fiat Chrysler

$23.39

-0.03 (-0.13%)

DDAIF

Daimler AG

$90.25

1.44 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAC

GAP Airports

$102.12

0.45 (0.44%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Earnings
GAP Airports sees FY18 total revenue growth 13%, plus or minus 1% »

FY18 revenue consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.76

-0.26 (-1.37%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Hot Stocks
GE Capital to fund contributions, suspend dividend to GE for forseeable future »

GE Capital to fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

K

Kellogg

$64.69

-1.29 (-1.96%)

, CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Recommendations
Kellogg, Campbell Soup analyst commentary  »

Kellogg added to U.S.…

K

Kellogg

$64.69

-1.29 (-1.96%)

CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

GE

General Electric

$18.76

-0.26 (-1.37%)

06:39
01/16/18
01/16
06:39
01/16/18
06:39
Hot Stocks
GE to take $6.2B charge in Q4 on insurance operations »

GE announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

CPB

Campbell Soup

$45.51

-0.24 (-0.52%)

06:37
01/16/18
01/16
06:37
01/16/18
06:37
Upgrade
Campbell Soup rating change  »

Campbell Soup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$24.01

0.63 (2.69%)

06:36
01/16/18
01/16
06:36
01/16/18
06:36
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$126.96

1.52 (1.21%)

06:35
01/16/18
01/16
06:35
01/16/18
06:35
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$27.53

0.38 (1.40%)

06:34
01/16/18
01/16
06:34
01/16/18
06:34
Periodicals
Airbus prepared to shut down production of A380 superjumbo, FT reports »

Airbus is ready to shut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$34.63

2.54 (7.92%)

06:34
01/16/18
01/16
06:34
01/16/18
06:34
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.81

1.47 (8.48%)

06:33
01/16/18
01/16
06:33
01/16/18
06:33
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$36.73

0.53 (1.46%)

06:32
01/16/18
01/16
06:32
01/16/18
06:32
Upgrade
21st Century Fox rating change  »

21st Century Fox upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

DUST

Direxion Daily Gold Miners Bear 3X ETF

$21.30

-1.89 (-8.15%)

06:32
01/16/18
01/16
06:32
01/16/18
06:32
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SP

SP Plus Corp.

$38.00

0.2 (0.53%)

06:31
01/16/18
01/16
06:31
01/16/18
06:31
Hot Stocks
SP Plus Corp. sells joint venture interest in Parkmobile, sees Q1 gain »

SP Plus Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$47.10

-4.42 (-8.58%)

06:31
01/16/18
01/16
06:31
01/16/18
06:31
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$25.85

0.01 (0.04%)

06:30
01/16/18
01/16
06:30
01/16/18
06:30
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLB

Dolby

$65.35

1.06 (1.65%)

06:29
01/16/18
01/16
06:29
01/16/18
06:29
Downgrade
Dolby rating change  »

Dolby downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$144.75

-0.25 (-0.17%)

06:29
01/16/18
01/16
06:29
01/16/18
06:29
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$76.84

1.28 (1.69%)

06:28
01/16/18
01/16
06:28
01/16/18
06:28
Periodicals
Citi results likely 'overwhelmed' by $20B charge due to tax overhaul, WSJ says »

Citigroup's results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

JPM

JPMorgan

$112.67

1.83 (1.65%)

06:28
01/16/18
01/16
06:28
01/16/18
06:28
Hot Stocks
JPMorgan reports December net credit losses 2.43% vs. 2.36% last month »

Reports December 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$4.74

0.01 (0.21%)

06:27
01/16/18
01/16
06:27
01/16/18
06:27
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNV

Innovus Pharmaceuticals

06:27
01/16/18
01/16
06:27
01/16/18
06:27
Hot Stocks
Innovus Pharmaceuticals' hemorrhoid drug Xyralid approved in Canada »

Innovus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.